Overactive Bladder: Definition, Etiology, Prevalence, and Cost

Consultant Pharmacist

Volumn 18, Issue SUPPL. B, 2003, Pages 4-12

  Dutcher, Judy A ^a   Miller, Susan W ^b  

^a Clinical Services   (United States)

^b MERCER UNIVERSITY   (United States)

Author keywords

Incontinence; Overactive bladder; Pharmacoeconomics; Prevalence; Quality of life; Urinary tract

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; BLADDER FILLING; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE STUDY; DETRUSOR MUSCLE; DIABETES MELLITUS; DISEASE COURSE; DRUG COST; DRUG FORMULATION; ELDERLY CARE; EPIDEMIOLOGICAL DATA; FALLING; FEMALE; HEALTH CARE COST; HUMAN; ILLNESS BEHAVIOR; LONG TERM CARE; MALE; NOMENCLATURE; OSTEOPOROSIS; OVERACTIVE BLADDER; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SKIN DISEASE; UNITED STATES; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY;

EID: 0842342685     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Resnick NM. Improving treatment of urinary incontinence. JAMA 1998;280:2034-5.
2. Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J Urol 2003;169:843-8.
3. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol and Urodyn 2002;21:1670-8.
4. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002;60(5, suppl 1):82-9.
5. MEDLINEplus Health Information. Urge Incontinence. Available at http://www.nlm.nih.gov/medlineplus/ency/article/001270.htm. Accessed May 2003.
6. Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Ann Pharmacother 1999;33:1073-82.
7. Guyton AC, Hall JE. Micturition, diuretics, and kidney diseases. In: Textbook of medical physiology, 10th ed. Philadelphia, PA: WB Saunders Company; 2000.
8. Ouslander JG. Geriatric urinary incontinence. Disease-a-Month 1992;38:1-140.
9. Payne CK. Epidemiology, pathophysiology, and evaluation of urinary incontinence and overactive bladder. Urology 1998;51(2A, suppl):3-10.
10. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002;60 (suppl 5A):49-55.
11. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5.
12. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability, and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-95.
13. Leung HY, Yip SK, Cheon C et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 2002;90:375-80.
14. American Foundation for Urologic Disease Web site. Available at http://www.afud.org/membership.html. Accessed April 2003.
15. Burnett A. The impact of urinary incontinence. MCConsultant 2002; 2:6-12.
16. National Institutes of Health. Osteoporosis and related bone diseases: national resource center web site. Available at http://www.osteo.org/osteo.html. Accessed February 2001.
17. Samuelsson E, Victor A, Tibblin G. A population study of urinary incontinence and nocturia among women aged 20-59 years. Prevalence, well-being and wish for treatment. Acta Obstet Gynecol Scand 1997;76:74-80.
18. National Institute on Aging. General information on Alzheimer's disease. Available at http://www.alzheimers.org/generalinfo.htm. Accessed April 2003.
19. Abrams P, Wein AJ. Introduction: overactive bladder and its treatments. Urology 2000;55(suppl 5A):1-2.
20. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998;46:473-80.
21. Simeonova Z, Milsom I, Kullendorff AM et al. The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. Acta Obstet Gynecol Scand 1999;78:546-51.
22. Brown JS, Grady D, Ouslander JG et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol 1999;94:66-70.
23. Milsom I, Abrams P, Cardoza L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Inter 2001;87:760-6.
24. Newman DK. Urinary incontinence and overactive bladder: identification of those persons at risk. Topics in Advanced Practice Nursing eJournal 2001;1:1-3. Available at http://www.medscape.com/viewarticle/408405_3. Accessed April 2003.
25. Ouslander JG. Incontinence management in long-term care. Annals of Long-Term Care 2000; MultiMedia Health-Care/Freedom, LLC. Available at http://www.mmhc.com/nhm/articles/NHM0006/ouslander.html. Accessed May 2003.
26. Brown JS, Saways G, Thom DH. Hysterectomy and urinary incontinence: a systematic review. Lancet 2000;56:535-9.
27. Ouslander JG, Shih YT, Lee JM, Luber K. Overactive bladder: special considerations in the geriatric population. Am J Manag Care 2000;6(11, suppl):S599-S606.
28. Smoger SH, Felice TL, Kloecker GH. Urinary incontinence among male veterans receiving care in primary care clinics. Ann Intern Med 2000;132:547-51.
29. Wagner T, Hu T, Bentkover J et al. on behalf of the NOBLE Program Research Team. Economic costs of overactive bladder (abstract). Accepted for presentation at the 2nd International Consultation on Incontinence; July 1-3, 2001; Paris, France.
30. Lear BK. Squeeze when you sneeze. Available at http://www.excelrehab.com/squeeze.html. Accessed April 2003.
31. Lackner T, Maloney C. Diagnosing and treating urinary incontinence. ASCP. Available at http://www.ascp.com/public/pubs/tcp/1999/special/diagnosing.shtml. Accessed April 2003.
32. Wilson I, Brown JS, Shin GP et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001;98:398-406.
33. Cochran A. Don't ask, don't tell: the incontinence conspiracy. Manag Care Q 2000;8:44-32.
34. Federal Trade Commission. Extended release treatment for overactive bladder. Press Release April 14, 2003. Available at http://www.ftc.gov/opa/2003/04/pfizer.htm. Accessed April 2003.
35. Novartis AG. Novarris to acquire Enablex: (darifenacin), a new incontinence treatment for a rapidly expanding population of patients, from Pfizer. Media release March 18, 2003. Available at http://www.novartis.com. Accessed April 2003.
36. CNN Money. Competition concerns. Available at http.//money.cnn.com/2003/03/18/news/companies/Pfizer_novartis.reut. Accessed April 2003.
37. 2003 Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc; 2003.
38. Bitz K. Soaking up sales in adult incontinence. Available at www.nonwovens-industry.com/mar012.htm. Accessed April 2003.
39. Noe I, Becker R, Williamson T, Chen D. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002;5:343-52.
40. Brown JS, Vittinghoff E, Wyman JF et al. Urinary incontinence: does it increase risk for falls and fractures? J Am Geriatr Soc 2000;4:721-5.
41. Hu T, Wagner T, Bentkover J et al. Health related consequences of overactive bladder. Am J Manag Care 2002;8(19, suppl):S598-S607.
42. Ouslander JG, Palmer MH, Rovner BW et al. Urinary incontinence in nursing homes: incidence remission and associated factors. J Am Geriatr Soc 1993;41: 1083-9.
43. Hu T. Impact of urinary incontinence on health care cost. J Am Geriatr Soc 1990;38:292-5.
44. The Long Term Care Alliance. Making a difference in senior care: a focus on bladder control problems. Center for Health Information 2001.
45. Maloney C, Cafiero M. Urinary incontinence: maximizing outcomes in long-term care. Annals of Long-Term Care: Clinical Care and Aging 2002;8:21-4.
46. Weiss BD. Diagnostic evaluation of urinary incontinence in geriatric patients. Am Fam Physician 1998; 12: Available at http://www.aafp.org/afp/980600ap/weiss.html. Accessed April 2003.
47. Dugan E, Cohen SJ, Bland DR et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc 2000;48:413-6.
48. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 1999;44:56-66.
49. Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83:583-90.
50. Agency for Healthcare Research and Quality. AHRQ focus on research: Long-term care. Available at http://www:ahcpr.gov/news/focus/focltcare.htm. Accessed April 2003.